Epidemiology of ovarian cancer
- PMID:32648448
- DOI: 10.21037/cco-20-34
Epidemiology of ovarian cancer
Abstract
Worldwide, ovarian cancer (OC) is the seventh most common type of malignant neoplasm in women and the eighth cause of mortality in them. The classification of OC is made by the possible origin of one of the three main components of the ovary: epithelium, stroma, and germinal cells. Due to this the main malignant tumors arising from the ovary are epithelial carcinoma, germ cell tumor, sex cord-stromal tumor, and Krukenberg's tumor. The most common are the epithelial carcinomas, in which the most prevalent is serous ovarian carcinoma. Nevertheless, the subtype of OC varies according to the age of appearance. The global incidence of OC has been stable during the last decades, but, it´s still a disease that has contributed to a considerable number of deaths around the world. The epidemiology of this cancer shows differences between races and countries due to several factors including genetic and economic. The detection of this cancer has been problematic as there is no screening public program for its early detection and as a consequence, most OCs are detected in an advanced stage where most of the time it has already spread to other parts different from the ovary. The purpose of this article is to present a comprehensive review of the general epidemiology, incidence rates, prevalence rates, mortality, and survival of the different types of OC worldwide and in certain regions.
Keywords: Krukenberg’s tumor; Ovarian carcinoma (OC); epidemiology; germ cells tumor; incidence; mortality; sex cord stromal tumor; survival rates.
Similar articles
- Ovarian cancer in France: trends in incidence, mortality and survival, 1980-2012.Trétarre B, Molinié F, Woronoff AS, Bossard N, Bessaoud F, Marrer E, Grosclaude P, Guizard AV, Delafosse P, Bara S, Velten M, Lapôtre-Ledoux B, Ligier K, Léone N, Arveux P, Uhry Z.Trétarre B, et al.Gynecol Oncol. 2015 Nov;139(2):324-9. doi: 10.1016/j.ygyno.2015.09.013. Epub 2015 Sep 14.Gynecol Oncol. 2015.PMID:26383829
- Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.Matsuo K, Machida H, Mandelbaum RS, Grubbs BH, Roman LD, Sood AK, Gershenson DM.Matsuo K, et al.Gynecol Oncol. 2019 May;153(2):230-237. doi: 10.1016/j.ygyno.2019.02.003. Epub 2019 Feb 20.Gynecol Oncol. 2019.PMID:30797590Free PMC article.
- Prognostic factors of Krukenberg's tumor.Kim HK, Heo DS, Bang YJ, Kim NK.Kim HK, et al.Gynecol Oncol. 2001 Jul;82(1):105-9. doi: 10.1006/gyno.2001.6210.Gynecol Oncol. 2001.PMID:11426970
- Origin and molecular pathogenesis of ovarian high-grade serous carcinoma.Kurman RJ.Kurman RJ.Ann Oncol. 2013 Dec;24 Suppl 10:x16-21. doi: 10.1093/annonc/mdt463.Ann Oncol. 2013.PMID:24265397Review.
- From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.Young RH.Young RH.Adv Anat Pathol. 2007 May;14(3):149-77. doi: 10.1097/PAP.0b013e3180504abf.Adv Anat Pathol. 2007.PMID:17452813Review.
Cited by
- Filling the Gaps in Oncofertility Care by Addressing Challenges Faced by Patients and Providers.Ranjith S, Dave A.Ranjith S, et al.Cureus. 2023 Dec 9;15(12):e50219. doi: 10.7759/cureus.50219. eCollection 2023 Dec.Cureus. 2023.PMID:38192954Free PMC article.Review.
- Identification ofBRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients.Li J, Han S, Zhang C, Luo Y, Wang L, Wang P, Wang Y, Xia Q, Wang X, Wei B, Ma J, Li H, Guo Y.Li J, et al.Front Oncol. 2021 May 11;11:655709. doi: 10.3389/fonc.2021.655709. eCollection 2021.Front Oncol. 2021.PMID:34046351Free PMC article.
- Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer.Wu Y, Zhang X, Li L, Yang W, Yan Z, Gu C, Zhang Z, Zhou J, Liu L, Ye M, Meng Y.Wu Y, et al.Onco Targets Ther. 2022 Sep 12;15:973-979. doi: 10.2147/OTT.S375643. eCollection 2022.Onco Targets Ther. 2022.PMID:36118677Free PMC article.
- Splenectomy as Part of Maximal-Effort Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.Pergialiotis V, Zachariou E, Lygizos V, Vlachos DE, Stamatakis E, Angelou K, Daskalakis G, Thomakos N, Haidopoulos D.Pergialiotis V, et al.Cancers (Basel). 2024 Feb 15;16(4):790. doi: 10.3390/cancers16040790.Cancers (Basel). 2024.PMID:38398182Free PMC article.
- Whole-exome mutational landscape and molecular marker study in mucinous and clear cell ovarian cancer cell lines 3AO and ES2.Li J, Liang H, Xiao W, Wei P, Chen H, Chen Z, Yang R, Jiang H, Zhang Y.Li J, et al.BMC Cancer. 2023 Apr 6;23(1):321. doi: 10.1186/s12885-023-10791-9.BMC Cancer. 2023.PMID:37024829Free PMC article.
Publication types
MeSH terms
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical